ATHX
A strong opportunity to buy a company's stock
It may drop more, do not be afraid, it is a second opportunity to buy, I cannot determine the time when the company’s stock will rise, this is only known to the market maker, for this patience is important in trading a company’s stock
I can't explain the strategy, it's secret, I'm honored that you follow me on...
stopping out @ $1.30, no if and or butts this thing performs on the back of these latest impulses or audios amigo. $1.80 conceivable if it trades within it's box, alert set there. $6.31 gap fill would be great, but not realistic. My sense is it breaks down. No news on phase 2 for awhile....
Pupm&Dump trading strategy idea.
$ATHE is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $1,84;
stop-loss — $2,05;
take-profit — $1,42.
Do not view this idea as a recommendation for trading or investing. It is...
patent approvals, phases cleared, looks like a disruptive company doing good in the biotech space. 800 shares long, trading 1/2 the position around $2.50 today if it claws back up
this one has two gaps to be filled, so may be risky.
going long with a tight stop-loss.
target - previous highs.
if it drifts lower, will wait till the gaps are filled before buying again.
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The...
Retracing after gap up
More than 50% retraced alreday
Will probably fill Gap#2 with the next few days
A second target is fill gap#1 from june.
PT1 = 2,54 (filled)
PT2 = 1,56 (For Gap#2 fill)
Bonus PT3 = 1,12
Bonus PT4 = 0,60 (For gap #1 fill)
ATH should find support at the fib retracement ).782 level, rally off it to test and break the fib ext 0.382 level. with big news coming we could see a large run upwards.
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological...
Share prices fell sharply following a massive pump in yesterday's trades and closed around critical support at 0.138. Share prices will need to hold above 0.138 to head back up; support is at around 0.110 and major support at 0.069
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 (previously PBT434), the company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder.
The company recently...
ATH - Massive Pump, Important price level to watch
Major support - 0.293 and 0.195
Major resistance - 0.394 and 0.490
Share prices currently hold above 0.293 critical support level and could head back up to retest 0.394 if it remains above current support
